Laser treatment for eye degeneration gets FDA priority

17 Jun 2002

The US Food and Drug Administration (FDA) has granted priority review status to a laser therapy treatment for problems that affect peoples' eyes as they get older. The system treats a common form of eye degeneration and includes the verteportferin drug which is activated by a 689 nanometre diode laser.

The FDA is expected to act on the application, filed jointly by Coherent Medical and QLT PhotoTherapeutics, within six months.